Amylin to present diabetes drug data at ADA scientific meeting
SAN DIEGO Amylin Pharmaceuticals plans to present data on two of its diabetes drugs and an investigational diabetes drug at the annual scientific meeting of the American Diabetes Association in New Orleans next month, the drug maker announced Friday.
The company will present data on the injected drugs Byetta (exenatide) and Symlin (pramlintide acetate), as well as a once-weekly formulation of exenatide. All the drugs are designed to treat Type 2 diabetes, though Symlin also treats Type 1 diabetes. Amylin markets Byetta with Indianapolis-based Eli Lilly & Co.
The company said its presentation, which will include five oral presentations and 16 posters, would demonstrate “significant progress” in key research and clinical programs for the three drugs.
J&J: Agreements with Schering-Plough void after Merck merger
NEW BRUNSWICK, N.J. The planned merger between Schering-Plough Corp. and Merck & Co. would permit the termination of agreements between Schering-Plough and Johnson & Johnson’s biotech division, J&J asserted in an arbitration demand filed Wednesday with the American Arbitration Association, an alternative dispute resolution organization.
The drug maker said the planned merger constituted a change of control that would allow the termination between agreements its Centocor Ortho Biotech division made with Schering-Plough regarding the inflammatory and immunological disease drugs Remicade (infliximab) and Simponi (golimumab).
“As its public statements have made clear, Merck is acquiring Schering-Plough,” J&J said in a statement. “The acquisition constitutes a change of control that tribbers the right of our Centocor Ortho Biotech subsidiary to terminate the agreements.”
FDA accepts approval application from Warner Chilcott
ARDEE, Ireland The Food and Drug Administration has accepted an approval application for a low-dose oral contraceptive from Warner Chilcott, the drug maker announced Wednesday.
The agency accepted Warner Chilcott’s new drug application for WC 3016, submitted through a subsidiary on March 26.
The company recently relocated its headquarters from Bermuda to Ireland.